TVTX vs. KNSA
TVTX (Travere Therapeutics, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, TVTX returned 28.34%/yr vs 29.69%/yr for KNSA. At a 0.34 correlation, their price movements are largely independent.
Performance
TVTX vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TVTX achieves a 44.33% return, which is significantly higher than KNSA's 33.60% return.
TVTX
- 1D
- 1.87%
- 1M
- 24.13%
- YTD
- 44.33%
- 6M
- 59.81%
- 1Y
- 285.39%
- 3Y*
- 47.17%
- 5Y*
- 28.34%
- 10Y*
- 12.13%
KNSA
- 1D
- 1.66%
- 1M
- 3.51%
- YTD
- 33.60%
- 6M
- 27.60%
- 1Y
- 93.78%
- 3Y*
- 52.43%
- 5Y*
- 29.69%
- 10Y*
- —
TVTX vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
TVTX Travere Therapeutics, Inc. | 44.33% | 119.35% | 93.77% | -57.25% | -32.25% | 13.89% | 91.94% | -37.25% | -22.10% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 33.60% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between TVTX and KNSA is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.35 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.34 |
Fundamentals
TVTX:
$5.07B
KNSA:
$4.54B
TVTX:
-$0.49
KNSA:
$0.92
TVTX:
9.61
KNSA:
5.80
TVTX:
51.32
KNSA:
7.50
TVTX:
$536.20M
KNSA:
$754.05M
TVTX:
$385.20M
KNSA:
$294.06M
TVTX:
$11.15M
KNSA:
$101.06M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TVTX vs. KNSA — Risk / Return Rank
TVTX
KNSA
TVTX vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Travere Therapeutics, Inc. (TVTX) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TVTX | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.70 | ||
| Sortino ratioReturn per unit of downside risk | +1.23 | ||
| Omega ratioGain probability vs. loss probability | 1.58 | 1.41 | +0.17 |
| Calmar ratioReturn relative to maximum drawdown | 8.50 | 4.63 | +3.87 |
| Martin ratioReturn relative to average drawdown | 19.67 | 16.35 | +3.32 |
Loading charts...
Drawdowns
TVTX vs. KNSA - Drawdown Comparison
The maximum TVTX drawdown since its inception was -85.43%, roughly equal to the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for TVTX and KNSA.
Loading charts...
Drawdown Indicators
| TVTX | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.43% | -83.06% | -2.37% |
Max Drawdown (1Y)Largest decline over 1 year | -33.49% | -21.12% | -12.37% |
Max Drawdown (3Y)Largest decline over 3 years | -69.51% | -34.14% | -35.37% |
Max Drawdown (5Y)Largest decline over 5 years | -83.12% | -53.17% | -29.95% |
Max Drawdown (10Y)Largest decline over 10 years | -83.64% | — | — |
Current DrawdownCurrent decline from peak | 0.00% | -7.35% | +7.35% |
Average DrawdownAverage peak-to-trough decline | -41.02% | -40.60% | -0.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.45% | 5.97% | +8.48% |
Volatility
TVTX vs. KNSA - Volatility Comparison
Travere Therapeutics, Inc. (TVTX) has a higher volatility of 15.36% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 10.40%. This indicates that TVTX's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TVTX | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.36% | 10.40% | +4.96% |
Volatility (6M)Calculated over the trailing 6-month period | 52.61% | 34.02% | +18.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 71.64% | 43.03% | +28.61% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 66.50% | 53.48% | +13.02% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 58.37% | 63.93% | -5.56% |
Dividends
TVTX vs. KNSA - Dividend Comparison
Neither TVTX nor KNSA has paid dividends to shareholders.
Financials
TVTX vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Travere Therapeutics, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TVTX vs. KNSA - Profitability Comparison
TVTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 127.20M. Therefore, the gross margin over that period was 0.0%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
TVTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported an operating income of -36.60M and revenue of 127.20M, resulting in an operating margin of -28.8%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
TVTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a net income of -37.10M and revenue of 127.20M, resulting in a net margin of -29.2%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
Frequently Asked Questions
TVTX and KNSA have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TVTX has higher volatility (15.36%) compared to KNSA (10.40%). In terms of maximum drawdown, TVTX dropped -85.43% vs KNSA's -83.06%.
TVTX currently has the higher Sharpe Ratio (3.98 vs 2.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TVTX and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer